Exact Mass: 626.314955
Exact Mass Matches: 626.314955
Found 369 metabolites which its exact mass value is equals to given mass value 626.314955,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2-[4,7,10-Tris(carboxymethyl)-6-[4-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]butyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5))
PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0)
PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/10:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15))
PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0)
PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/10:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0)
PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/10:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0)
PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/10:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0)
PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/10:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0)
PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/10:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
1beta-acetoxy-9alpha-benzoyloxy-8beta-(beta-furancarbonyloxy)-6alpha-hydroxy-2beta-(alpha-methylbutanoyloxy)-beta-dihydroagarofuran
(6E,10Z)-12-acetoxy-5-hydroxy-beta-nerolidol-5-O-beta-D-tetraacetylglucopyranoside
5-((S)-7-Hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isochinolylmethyl)-4-(4-((S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isochinolylmethyl]-phenoxy)-2-methoxy-phenol|5-((S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isoquinolylmethyl)-4-(4-((S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1]isoquinolylmethyl]-phenoxy)-2-methoxy-phenol|Magnolamin|Magnolamine
C37H42N2O7 (626.2991862000001)
2-Cinnamoyl-(2beta,3beta,5beta,20R,22R,24S)-2,3,5,14,20,22,24-Heptahydroxycholest-7-en-6-one|Polypodin C2-cinnamat
(8aR,8aR,10aR,10aR)-1,2-bis(2-hydroxy-1-isopropyl-8a,10a-dimethyl-7,8,8a,9,10,10a-hexahydrobenzo[f]azulene-3,6-dion-5-yl)-ethane|radianspene M
3beta-benzoyloxy-5alpha,8alpha-diacetoxy-15beta-hydroxy-7beta-propanoyloxyjatropha-6(17),11E-diene-9,14-dione
Me glycoside,3,4,6-tribenzyl-2-O-alpha-D-Mannopyranosyl-D-mannose
(4aR,5S,6R,8aS)-5-[2-(2,5-dihydro-5-oxofuran-3-yl)ethyl]-3,4,4a,5,6,7,8,8a-octahydro-5,6,8a-trimethylnaphthalene-1-carboxylic acid (6-O-D-apio-beta-D-glucopyranosyl ester)|caseariaside C|cis-cleroda-3,13-diene-15,18-dioic acid 15,16-lactone 18-(6-O-beta-apiofuranosyl-beta-D-glucopyranosyl) ester
C34H42O11_7,11-Methano-2H-cycloocta[3,4]benzo[1,2-c]pyran-8-acetic acid, alpha-(acetyloxy)-4-(3-furanyl)-1,4,4a,5,6,6a,7,8,9,10,11,12-dodecahydro-11-hydroxy-4a,7,9,9-tetramethyl-10-[[(2E)-2-methyl-1-oxo-2-buten-1-yl]oxy]-2,13-dioxo-, methyl ester
Glu His Arg Trp
C28H38N10O7 (626.2924797999999)
Glu His Trp Arg
C28H38N10O7 (626.2924797999999)
Glu Arg His Trp
C28H38N10O7 (626.2924797999999)
Glu Arg Trp His
C28H38N10O7 (626.2924797999999)
Glu Trp His Arg
C28H38N10O7 (626.2924797999999)
Glu Trp Arg His
C28H38N10O7 (626.2924797999999)
Phe Phe Lys Trp
Phe Phe Gln Trp
Phe Phe Trp Lys
Phe Phe Trp Gln
Phe Lys Phe Trp
Phe Lys Trp Phe
Phe Gln Phe Trp
Phe Gln Trp Phe
Phe Trp Phe Lys
Phe Trp Phe Gln
Phe Trp Lys Phe
Phe Trp Gln Phe
His Glu Arg Trp
C28H38N10O7 (626.2924797999999)
His Glu Trp Arg
C28H38N10O7 (626.2924797999999)
His Arg Glu Trp
C28H38N10O7 (626.2924797999999)
His Arg Trp Glu
C28H38N10O7 (626.2924797999999)
His Val Trp Trp
His Trp Glu Arg
C28H38N10O7 (626.2924797999999)
His Trp Arg Glu
C28H38N10O7 (626.2924797999999)
His Trp Val Trp
His Trp Trp Val
Lys Phe Phe Trp
Lys Phe Trp Phe
Lys Met Trp Tyr
Lys Met Tyr Trp
Lys Trp Phe Phe
Lys Trp Met Tyr
Lys Trp Tyr Met
Lys Tyr Met Trp
Lys Tyr Trp Met
Met Lys Trp Tyr
Met Lys Tyr Trp
Met Trp Lys Tyr
Met Trp Tyr Lys
Met Tyr Lys Trp
Met Tyr Trp Lys
Gln Phe Phe Trp
Gln Phe Trp Phe
Gln Trp Phe Phe
Arg Glu His Trp
C28H38N10O7 (626.2924797999999)
Arg Glu Trp His
C28H38N10O7 (626.2924797999999)
Arg His Glu Trp
C28H38N10O7 (626.2924797999999)
Arg His Trp Glu
C28H38N10O7 (626.2924797999999)
Arg Trp Glu His
C28H38N10O7 (626.2924797999999)
Arg Trp His Glu
C28H38N10O7 (626.2924797999999)
Val His Trp Trp
Val Trp His Trp
Val Trp Trp His
Trp Glu His Arg
C28H38N10O7 (626.2924797999999)
Trp Glu Arg His
C28H38N10O7 (626.2924797999999)
Trp Phe Phe Lys
Trp Phe Phe Gln
Trp Phe Lys Phe
Trp Phe Gln Phe
Trp His Glu Arg
C28H38N10O7 (626.2924797999999)
Trp His Arg Glu
C28H38N10O7 (626.2924797999999)
Trp His Val Trp
Trp His Trp Val
Trp Lys Phe Phe
Trp Lys Met Tyr
Trp Lys Tyr Met
Trp Met Lys Tyr
Trp Met Tyr Lys
Trp Gln Phe Phe
Trp Arg Glu His
C28H38N10O7 (626.2924797999999)
Trp Arg His Glu
C28H38N10O7 (626.2924797999999)
Trp Val His Trp
Trp Val Trp His
Trp Trp His Val
Trp Trp Val His
Trp Tyr Lys Met
Trp Tyr Met Lys
Tyr Lys Met Trp
Tyr Lys Trp Met
Tyr Met Lys Trp
Tyr Met Trp Lys
Tyr Trp Lys Met
Tyr Trp Met Lys
ST 36:8;O9
2-dodecylcyclopenta-1,3-diene,zirconium(4+),dichloride
C34H58Cl2Zr (626.2962408000001)
guamecycline
C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic
benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid,propane-1,2-diol
3-[2-[[3-(2-carboxyethyl)-5-[(3-ethyl-4-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methylpyrrol-3-yl]propanoic acid,hydrochloride
TRIS(N-TERT-BUTYL-3,5-DIMETHYLANILINO)MOLYBDENUM(III)
(2R)-2,6-diaminohexanoic acid; (2R,4S)-2-({[(5R)-5-amino-5-carboxypentyl]carbamoyl}(2-phenylacetamido)methyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
Primary fluorescent chlorophyll catabolite(2-)
C35H38N4O7-2 (626.2740358000001)
3-[(3S,4S,5Z)-5-[(4-ethenyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methylidene]-2-[(2Z)-2-[(3-ethyl-5-formyl-4-methyl-1H-pyrrol-2-yl)methylidene]-4-hydroxy-5-methoxycarbonyl-3-methyl-1H-cyclopenta[b]pyrrol-6-yl]-4-methyl-3,4-dihydropyrrol-3-yl]propanoic acid
C35H38N4O7 (626.2740358000001)
3-[(21S,22S)-12-(dihydroxymethyl)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-17,19,21-trimethyl-11-propyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
C36H42N4O6 (626.3104192000001)
2-[[(2R)-3-acetyloxy-2-[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-15-[3-[(Z)-pent-2-enyl]oxiran-2-yl]pentadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(4Z,7Z,10Z,13Z)-15-[3-[(Z)-pent-2-enyl]oxiran-2-yl]pentadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
euphornin L
A macrocyclic diterpenoid isolated from Euphorbia helioscopia and has been shown to exhibit cytotoxicity against HL-60 cell lines.
3-[(3S,4S,5Z)-5-[(4-ethenyl-5-hydroxy-3-methyl-1H-pyrrol-2-yl)methylidene]-2-[2-[(3-ethyl-5-formyl-4-methyl-1H-pyrrol-2-yl)methyl]-5-methoxycarbonyl-3-methyl-4-oxo-1H-cyclopenta[b]pyrrol-6-yl]-4-methyl-3,4-dihydropyrrol-3-yl]propanoic acid
C35H38N4O7 (626.2740358000001)
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-icos-11-enoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate
[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] heptanoate
[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] octanoate
[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate
[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate
[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-hexadec-9-enoate
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-heptadec-9-enoate
[(2S,3S,6S)-6-[(2S)-2,3-di(decanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
C29H54O12S (626.3335804000001)
[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
Primary fluorescent chlorophyll catabolite(2-)
C35H38N4O7 (626.2740358000001)
Dianion of primary fluorescent chlorophyll catabolite.
1-(11Z-eicosenoyl)-glycero-3-phospho-(1-myo-inositol)
PI(19:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
15-[1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylbut-2-enoate
(1r,2r,4s,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
(1s,6s,7s,10s,11r,12r,14s,15s,16r,18s)-18-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl (2e)-2-methylbut-2-enoate
3-[5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-(1-hydroxyethyl)-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione
(1s,3as,5ar,7s,8s,9ar,9br,11ar)-3a,8-dihydroxy-9a,11a-dimethyl-5-oxo-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
(1s,2r,4s,5s,9r,10r,13r,14r,15r,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 3,5-bis(3-methylbut-2-en-1-yl)-4-[(2,4,6-trihydroxy-3,5-dimethoxycyclohexyl)oxy]benzoate
2-amino-3-{[(7z)-10-hydroxy-12-[(2e)-7-hydroxy-8-(2-hydroxy-6-oxo-4,5-dihydro-3h-pyridin-4-yl)-4-methyl-5-oxooct-2-en-2-yl]-9-methoxy-11-methyl-2-oxo-1-oxacyclododec-7-en-4-yl]sulfanyl}propanoic acid
17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate
(1r,2r,4s,5r,9r,10r,13r,14s,15s,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate
(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e)-6-oxotetradeca-2,4-dienoate
(1r,5r,6r,13r,16s)-16-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl (2e)-2-methylbut-2-enoate
(2s,4as,4br,7r,10ar)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one
(1r,2s,3r,4ar,5s,6r,8s,8ar)-5-[(2s,3as,5s,6ar)-5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl (2r,3s)-3-(acetyloxy)-2-methylbutanoate
10,10'-dihydroxy-2,2'-diisopropyl-4b,4'b,8,8,8',8'-hexamethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah-[4,4'-biphenanthrene]-3,3',9,9'-tetrone
5-carbamimidamido-2-({[1-(2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl)-4-methylpyrrolidin-2-yl](hydroxy)methylidene}amino)pentanoic acid
(2r,3r,4s,5s)-2-(3,5-dimethoxy-4-{[(2s)-1-(3,4,5-trimethoxyphenyl)propan-2-yl]oxy}phenyl)-3,4-dimethyl-5-(3,4,5-trimethoxyphenyl)oxolane
2-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one
4-[5-(2,3-dihydroxy-3-methylbutyl)-12-hydroxy-16-methoxy-8,8,21,21-tetramethyl-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid
(1r,2r,4r,6s,8r,11r,12r,13s,16s,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,15-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
(1s)-1-{[2-hydroxy-3-(4-{[(1r)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenoxy)-4-methoxyphenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol
C37H42N2O7 (626.2991862000001)
2,3,5-trihydroxy-4,6-dimethoxycyclohexyl 3,5-bis(3-methylbut-2-en-1-yl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoate
[(2s,3s,3ar,4s,5r,6s,6as,7r,8r,10r,10ar,10bs)-7-(benzoyloxy)-3,3a,4,5,6,8,10a-heptahydroxy-2,10-dimethyl-8-(prop-1-en-2-yl)-decahydrocyclohexa[e]azulen-5-yl]methyl benzoate
(1s,3as,5as,7r,8r,9ar,9bs,11ar)-3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl (2e)-3-phenylprop-2-enoate
(4bs,4'bs,8as,8'as)-10,10'-dihydroxy-2,2'-diisopropyl-4b,4'b,8,8,8',8'-hexamethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah-[4,4'-biphenanthrene]-3,3',9,9'-tetrone
(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-2-{[(2s,4as,8ar)-5-[2-(furan-3-yl)ethyl]-1,1,4a,6-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
17-{[6-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-17-(hydroxymethyl)-12-methyl-8-oxapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-5-en-7-one
(1r,2r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
n-[(3r,4s,7s,10r,15as)-5,8-dihydroxy-7,10-bis(1h-indol-3-ylmethyl)-3-methyl-1,11-dioxo-3h,4h,7h,10h,13h,14h,15h,15ah-pyrrolo[2,1-c]1-oxa-4,7,10-triazacyclotridecan-4-yl]propanimidic acid
(1s)-4-[(3e,5e,7e,9e,11e)-12-[(2r)-4-[(1e)-2-[(1s,4s,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]ethenyl]-5-oxo-2h-furan-2-yl]-3,10-dimethyldodeca-3,5,7,9,11-pentaen-1-yn-1-yl]-3,5,5-trimethylcyclohex-3-en-1-yl acetate
(1s,2r,4s,5r,6s,7r,8r,9s,12r)-5-(acetyloxy)-7-(benzoyloxy)-12-hydroxy-2,6,10,10-tetramethyl-4-{[(2r)-2-methylbutanoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl furan-3-carboxylate
17,19-bis(acetyloxy)-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate
2-(3,5-dimethoxy-4-{[1-(3,4,5-trimethoxyphenyl)propan-2-yl]oxy}phenyl)-3,4-dimethyl-5-(3,4,5-trimethoxyphenyl)oxolane
(4as,4'as,10as,10'as)-5,5'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,10ah,10'ah-[9,9'-biphenanthrene]-6,6',10,10'-tetrone
(1s,3as,5as,7r,8s,9ar,9bs,11ar)-3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-[(2r,3r,5s)-2,3,5-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl (2e)-3-phenylprop-2-enoate
(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl (4ar,5s,6r,8as)-5,6,8a-trimethyl-5-[2-(5-oxo-2h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylate
(1s,2r,4s,5r,9r,10r,13r,14s,15s,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2z)-2-methylbut-2-enoate
2-amino-3-({10-hydroxy-12-[7-hydroxy-8-(2-hydroxy-6-oxo-4,5-dihydro-3h-pyridin-4-yl)-4-methyl-5-oxooct-2-en-2-yl]-9-methoxy-11-methyl-2-oxo-1-oxacyclododec-7-en-4-yl}sulfanyl)propanoic acid
(1r,6r,7r,10r,11s,12s,14r,15s,16s,18r)-14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl (2e)-2-methylbut-2-enoate
(1r,2r,4s,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
2-hydroxy-5-(2-{2-hydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl}ethyl)-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione
(1s,3r,4r,5s,9s,13r,14s)-3-[(2r,5r)-5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-[(1s)-1-hydroxyethyl]-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione
(1r,6r,7r,10r,11s,12s,14r,15s,16s,18r)-18-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl (2e)-2-methylbut-2-enoate
(2z)-4-[(1r,2r,15s,16r,17r,19s)-5-[(2r)-2,3-dihydroxy-3-methylbutyl]-12-hydroxy-16-methoxy-8,8,21,21-tetramethyl-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid
(1r,2r,5s,6s,8r,10s,11s,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-6-(furan-3-yl)-1,5,11,16-tetramethyl-7-oxo-9,14-dioxahexacyclo[11.6.1.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰.0¹⁶,²⁰]icosan-12-yl 2-methylbutanoate
(1'r,2r,4's,5s,6r,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl (2e)-2-methylbut-2-enoate
(1s,3r,4s,5s,9r,13s,14r)-3-[(2s,5r)-5-(4-chloro-3-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-[(1s)-1-hydroxyethyl]-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1¹,⁵]octadecane-7,11-dione
(1s,2s,3ar,4s,5s,9r,11r,13as)-3a,4,9,11-tetrakis(acetyloxy)-2,5,8,8,12-pentamethyl-1h,2h,3h,4h,5h,9h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate
(6r,7r,10r,11s,12s,14r,15r,18r)-14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl (2e)-2-methylbut-2-enoate
(1r,2r,4s,5s,9r,10r,13s,14s,15s,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl (2e)-2-methylbut-2-enoate
1-[(4-{4-hydroxy-2-[(7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-5-methoxyphenoxy}phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol
C37H42N2O7 (626.2991862000001)
(1s)-1-{[4-(4-hydroxy-2-{[(1s)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-methoxyphenoxy)phenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol
C37H42N2O7 (626.2991862000001)
16-[1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylbut-2-enoate
18-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl 2-methylbut-2-enoate
5-[(benzoyloxy)methyl]-3,3a,4,5,6,8,10a-heptahydroxy-2,10-dimethyl-8-(prop-1-en-2-yl)-decahydrocyclohexa[e]azulen-7-yl benzoate
(1r,6s,7s,10s,11s,12r,14r,15r,16s,18s)-14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl (2z)-2-methylbut-2-enoate
3a,8-dihydroxy-9a,11a-dimethyl-5-oxo-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl 3-(4-hydroxyphenyl)prop-2-enoate
{[(1s,4e,6r,8s,9s,10e,12s,13r,14s,16r,20s)-3,6,13,20-tetrahydroxy-8,14,19-trimethoxy-20-(methoxycarbonyl)-4,10,12,16-tetramethyl-21-oxo-2-azabicyclo[16.2.1]henicosa-2,4,10,18-tetraen-9-yl]oxy}methanimidic acid
3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl 3-phenylprop-2-enoate
(2r)-2-amino-3-{[(4r,7e,9r,10r,11r,12r)-10-hydroxy-12-[(2z,4r,7s)-7-hydroxy-8-(2-hydroxy-6-oxo-4,5-dihydro-3h-pyridin-4-yl)-4-methyl-5-oxooct-2-en-2-yl]-9-methoxy-11-methyl-2-oxo-1-oxacyclododec-7-en-4-yl]sulfanyl}propanoic acid
3a,5a,7-trihydroxy-9a,11a-dimethyl-5-oxo-1-(2,3,5-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-yl 3-phenylprop-2-enoate
5-(acetyloxy)-7-(benzoyloxy)-12-hydroxy-2,6,10,10-tetramethyl-4-[(2-methylbutanoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl furan-3-carboxylate
4-{12-[4-(2-{4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl}ethenyl)-5-oxo-2h-furan-2-yl]-3,10-dimethyldodeca-3,5,7,9,11-pentaen-1-yn-1-yl}-3,5,5-trimethylcyclohex-3-en-1-yl acetate
(2z)-3-[(1r,2s,3s,4r)-2-(2h-1,3-benzodioxol-5-yl)-4-[(5e)-6-(2h-1,3-benzodioxol-5-yl)hex-5-en-1-yl]-3-(piperidine-1-carbonyl)cyclobutyl]-1-(piperidin-1-yl)prop-2-en-1-one
C38H46N2O6 (626.3355696000001)
8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5-{5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl}-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl 3-(acetyloxy)-2-methylbutanoate
14-(acetyloxy)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-18-yl 2-methylbut-2-enoate
4,21',24'-trihydroxy-5,11',13',22'-tetramethyl-6-(4-methylpent-2-en-2-yl)-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraene-2',18'-dione
5,5'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,10ah,10'ah-[9,9'-biphenanthrene]-6,6',10,10'-tetrone
17,19-bis(acetyloxy)-8-(furan-3-yl)-4-hydroxy-1,9,11,16-tetramethyl-5,15-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate
6-{3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-(benzoyloxy)-6-hydroxy-2-methylheptan-2-yl acetate
3-[2-(2h-1,3-benzodioxol-5-yl)-4-[6-(2h-1,3-benzodioxol-5-yl)hex-5-en-1-yl]-3-(piperidine-1-carbonyl)cyclobutyl]-1-(piperidin-1-yl)prop-2-en-1-one
C38H46N2O6 (626.3355696000001)